文献速递炎症性肠病消化内镜

透壁愈合与MRI愈合较内镜黏膜愈合更能降低克罗恩病肠道损伤进展风险

Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
PubMed 文献 · Aliment Pharmacol Ther · 2020-12-28

该回顾性研究纳入154例克罗恩病患者,评估透壁愈合、MRI愈合与内镜黏膜愈合对长期结局的预测价值。结果显示透壁愈合和MRI愈合较内镜黏膜愈合与更低的肠道损伤进展风险相关,且透壁愈合还降低复发相关停药风险,提示二者可能是更优治疗目标。

要点

  • 透壁愈合和MRI愈合较内镜黏膜愈合与更低的肠道损伤进展风险相关。
  • 透壁愈合或MRI愈合较内镜黏膜愈合降低主要不良结局风险。
  • 透壁愈合较内镜黏膜愈合降低复发相关停药风险。

核心结论

  • 透壁愈合和MRI愈合较内镜黏膜愈合与更低的肠道损伤进展风险相关,可能作为克罗恩病更优的治疗目标。

研究设计与样本

  • 回顾性研究,从MRI数据库识别3个月内同时接受MRI和结肠镜检查的克罗恩病患者,中位间隔17.5天,共154例。

主要发现

  • 154例中无愈合51.9%(80/154)、内镜黏膜愈合10.4%(16/154)、MRI愈合19.5%(30/154)、透壁愈合18.2%(28/154)。
  • 透壁愈合较内镜黏膜愈合与更低的肠道损伤进展风险相关(HR=0.05 [0.00-0.40],P=0.002)。
  • MRI愈合较内镜黏膜愈合与更低的肠道损伤进展风险相关(HR=0.09 [0.00-0.47],P=0.005)。
  • 透壁愈合或MRI愈合较内镜黏膜愈合降低主要不良结局风险(HR=0.28 [0.00-0.74],P=0.01)。
  • 透壁愈合较内镜黏膜愈合降低复发相关停药风险(HR=0.35 [0.13-0.95],P=0.039)。

临床怎么用

  • 在克罗恩病治疗目标评估中,可考虑将透壁愈合或MRI愈合作为超越内镜黏膜愈合的更深层目标。

局限性

  • 回顾性研究设计,样本量154例,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic mucosal healing is the current therapeutic target in Crohn's disease. However, transmural healing could lead to better outcomes. AIMS: To assess whether transmural healing or magnetic resonance imaging (MRI) healing are better therapeutic targets than endoscopic mucosal healing to predict long-term improved outcome in Crohn's disease METHODS: From our MRI database, we retrospectively identified all Crohn's disease patients who had MRI and colonoscopy within a 3-month interval (median interval = 17.5 days). Four groups were considered: endoscopic mucosal healing (no ulceration or aphthoid erosion), MRI healing (no MRI signs of inflammation and no complication), transmural healing (combination of endoscopic and MRI healing) or no healing. Outcomes were time to surgery, bowel damage progression, hospitalisation, major outcomes (one of the three previous endpoints) and Crohn's disease-related drug discontinuation. Results were expressed in multivariable analyses adjusted on potential confounders (hazard ratio (HR) [95% confidence interval]). RESULTS: Among 154 patients with Crohn's disease, 51.9% (80/154), 10.4% (16/154), 19.5% (30/154) and 18.2% (28/154) achieved no healing, endoscopic mucosal healing, MRI healing and transmural healing, respectively. Transmural healing (HR = 0.05 [0.00-0.40], P = 0.002) and MRI healing (HR = 0.09 [0.00-0.47], P = 0.005) were associated with lower risk of bowel damage progression than endoscopic mucosal healing. In addition, achieving transmural healing or MRI healing reduced the risk of experiencing major outcomes compared to endoscopic mucosal healing (HR = 0.28 [0.00-0.74], P = 0.01). Patients with transmural healing also had a decreased risk of relapse-related drug discontinuation (HR = 0.35 [0.13-0.95], P = 0.039) compared to those with endoscopic mucosal healing. CONCLUSION: Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing and could be considered as better therapeutic targets in Crohn's disease.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lafeuille P, Hordonneau C, Vignette J, et al. Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease. Aliment Pharmacol Ther. 2020. PMID: 33368525. doi:10.1111/apt.16232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。